Systemic administration of β-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer

References

• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15. doi:10.1038/nm1100. PMID:15340416
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131–45. doi:10.1111/j.1600-065X.2006.00442.x. PMID:16972901
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. doi:10.1126/science.1203486. PMID:21436444
   PubMed Web of Science ®Google Scholar
• Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2:25. doi:10.1186/1756-8722-2-25. PMID:19515245
   PubMed Web of Science ®Google Scholar
• Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther. 2005;5(5):691–702. doi:10.1517/14712598.5.5.691. PMID:15934844
   PubMed Web of Science ®Google Scholar
• Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, Yan J. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells ia complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol. 2006;177(3):1661–9. doi:10.4049/jimmunol.177.3.1661. PMID:16849475
   PubMed Web of Science ®Google Scholar
• Liu J, Gunn L, Hansen R, Yan J. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp Mol Pathol. 2009;86(3):208–14. doi:10.1016/j.yexmp.2009.01.006. PMID:19454271
   PubMed Web of Science ®Google Scholar
• Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest. 1996;98(1):50–61. doi:10.1172/JCI118777. PMID:8690804
   PubMed Web of Science ®Google Scholar
• Xia, Y, Ross GD. Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18). J Immunol. 1999;162(12):7285–93. PMID:10358177
   PubMed Web of Science ®Google Scholar
• Bose N, Chan AS, Guerrero F, Maristany CM, Qiu X, Walsh RM, Ertelt KE, Jonas AB, Gorden KB, Dudney CM, et al. Binding of Soluble Yeast beta-Glucan to human neutrophils and monocytes is complement-dependent. Front Immunol. 2013;4:230. doi:10.3389/fimmu.2013.00230. PMID:23964276
   PubMed Web of Science ®Google Scholar
• Liu M, Luo F, Ding C, Albeituni S, Hu X, Ma Y, Cai Y, McNally L, Sanders MA, Jain D, et al. Dectin-1 activation by a natural product beta-glucan converts Immunosuppressive Macrophages into an M1-like Phenotype. J Immunol. 2015;195(10):5055–65. doi:10.4049/jimmunol.1501158. PMID:26453753
   PubMed Web of Science ®Google Scholar
• Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173(2):797–806. doi:10.4049/jimmunol.173.2.797. PMID:15240666
   PubMed Web of Science ®Google Scholar
• Vannucci L, Krizan J, Sima P, Stakheev D, Caja F, Rajsiglova L, Horak V, Saieh M. Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol. 2013;43(2):357–64. doi:10.3892/ijo.2013.1974. PMID:23739801
   PubMed Web of Science ®Google Scholar
• Samuelsen AB, Schrezenmeir J, Knutsen SH. Effects of orally administered yeast-derv ed beta-glucans: a review. Mol Nutr Food Res. 2014;58(1):183–93. doi:10.1002/mnfr.201300338. PMID:24019098
   PubMed Web of Science ®Google Scholar
• Muta T. Molecular basis for in ertebrate innate immune recognition of (1->3)-beta-D-glucan as a pathogen-associated molecular pattern. Curr Pharm Des. 2006;12(32):4155–61. doi:10.2174/138161206778743529. PMID:17100618
   PubMed Web of Science ®Google Scholar
• Ezekowitz RA, Sim RB, Hill M, Gordon S. Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med. 1984;159(1):244–60. doi:10.1084/jem.159.1.244. PMID:6319531
   PubMed Web of Science ®Google Scholar
• Tani M, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Noguchi K, Tamai M, Hotta T, Mizobata S. Augmentation of lymphokine-acti ated killer cell acti ity by lentinan. Anticancer Res. 1993;13(5C):1773–6. PMID:8267381
   PubMed Web of Science ®Google Scholar
• Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood. 2011;117(25):6825–36. doi:10.1182/blood-2011-02-339812. PMID:21531981
   PubMed Web of Science ®Google Scholar
• Li B, Cramer D, Wagner S, Hansen R, King C, Kakar S, Ding C, Yan J. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines ia MyD88- and Syk kinase-dependent pathways. Clin Immunol. 2007;124(2):170–81. doi:10.1016/j.clim.2007.05.002. PMID:17572156
   PubMed Web of Science ®Google Scholar
• Zhang M, Kim JA. Effect of molecular size and modification pattern on the internalization of water soluble beta-(1 ->3)-(1 ->4)-glucan by primary murine macrophages. Int J Biochem Cell Biol. 2012;44(6):914–27. doi:10.1016/j.biocel.2012.02.018. PMID:22679629
   PubMed Web of Science ®Google Scholar
• Choromanska A, Kulbacka J, Rembialkowska N, Pilat J, Oledzki R, Harasym J, Saczko J. Anticancer properties of low molecular weight oat beta-glucan - An in vitro study. Int J Biol Macromol. 2015;80:23–8. doi:10.1016/j.ijbiomac.2015.05.035. PMID:26092171
   PubMed Web of Science ®Google Scholar
• Cheung NK, Modak S. Oral (1->3),(1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8(5):1217–23. PMID:12006541
   PubMed Web of Science ®Google Scholar
• Yi H, Yu X, Gao P, Wang Y, Baek SH, Chen X, Kim HL, Subjeck JR, Wang XY. Pattern recognition sca enger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood. 2009;113(23):5819–28. doi:10.1182/blood-2008-11-190033. PMID:19349620
   PubMed Web of Science ®Google Scholar
• Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011;121(10):3846–59. doi:10.1172/JCI44952. PMID:21926464
   PubMed Web of Science ®Google Scholar
• Yi H, Guo C, Yu X, Gao P, Qian J, Zuo D, Manjili MH, Fisher PB, Subjeck JR, Wang X. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell accine-induced T-cell response and antitumor immunity. Cancer Res. 2011;71(21):6611–20. doi:10.1158/0008-5472.CAN-11-1801. PMID:21914786
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011;241(1):104–18. doi:10.1111/j.1600-065X.2011.01007.x. PMID:21488893
   PubMed Web of Science ®Google Scholar
• Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, Coussens LM, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11(11):986–994. doi:10.1038/nnano.2016.168. PMID:27668795
   PubMed Web of Science ®Google Scholar
• Parzonko A, Makarewicz-Wujec M, Jaszewska E, Harasym J, Kozłowska-Wojciechowska M. Pro-apoptotic properties of (1,3)(1,4)-beta-D-glucan from Avena sativa on human melanoma HTB-140 cells in vitro. Int J Biol Macromol. 2015;72:757–63. doi:10.1016/j.ijbiomac.2014.09.033. PMID:25285849
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5. doi:10.1038/nature14404. PMID:25970248
   PubMed Web of Science ®Google Scholar
• Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour ascular checkpoints. Nat Commun. 2015;6:7458. doi:10.1038/ncomms8458. PMID:26109379
   PubMed Web of Science ®Google Scholar